Long-term treatment of @entity309 comparing XXXX with @entity117 .

@entity1 @entity2852 @entity137 @entity117 @entity2416 @entity7127 @entity392 @entity490 @entity309
This report summarizes the results of a 17-investigator multicenter six-month randomized double-blind parallel group study. The safety and efficacy of @entity2852 1,000 mg taken at bedtime was compared with that of @entity117 900 mg four times daily in the treatment of adult @entity1 with active class II or III classical or definite @entity309 . Two hundred sixty-four @entity1 were entered into the study. Two hundred fifty-seven (126 @entity2852 and 131 @entity117 ) @entity1 were evaluable for safety. Two hundred thirty-four (113 @entity2852 and 121 @entity117 ) @entity1 were evaluable for efficacy. There was significant improvement in each of six clinical measurements of efficacy in both treatment groups and little difference between groups. The somewhat greater improvement in articular index and duration of @entity7127 in the @entity2852 -treated group did not reach statistical significance. There was an equal percentage of @entity1 withdrawal for lack of efficacy in each group. Overall, the rate of @entity1 withdrawal due to adverse experiences was greater (p = 0.01) for @entity117 -treated @entity1 . These experiences were @entity2416 , @entity490 , and @entity392 . It was concluded that @entity2852 was an effective anti-inflammatory drug in the treatment of @entity309 with less @entity137 than @entity117 .
